InflaRx N.V (NASDAQ: IFRX) has experienced a decline in its stock price by -12.57 compared to its previous closing price of 1.83. However, the company has seen a fall of -20.00% in its stock price over the last five trading days. globenewswire.com reported 2025-02-18 that JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares.
Is It Worth Investing in InflaRx N.V (NASDAQ: IFRX) Right Now?
Additionally, the 36-month beta value for IFRX is 1.95. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IFRX is 55.67M and currently, short sellers hold a 0.75% ratio of that float. The average trading volume of IFRX on February 25, 2025 was 359.49K shares.
IFRX’s Market Performance
The stock of InflaRx N.V (IFRX) has seen a -20.00% decrease in the past week, with a -32.49% drop in the past month, and a -16.67% fall in the past quarter. The volatility ratio for the week is 10.94%, and the volatility levels for the past 30 days are at 9.23% for IFRX. The simple moving average for the last 20 days is -29.52% for IFRX’s stock, with a simple moving average of -10.51% for the last 200 days.
Analysts’ Opinion of IFRX
Many brokerage firms have already submitted their reports for IFRX stocks, with Guggenheim repeating the rating for IFRX by listing it as a “Buy.” The predicted price for IFRX in the upcoming period, according to Guggenheim is $8 based on the research report published on April 05, 2023 of the previous year 2023.
Raymond James gave a rating of “Strong Buy” to IFRX, setting the target price at $14 in the report published on October 28th of the previous year.
IFRX Trading at -32.05% from the 50-Day Moving Average
After a stumble in the market that brought IFRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.16% of loss for the given period.
Volatility was left at 9.23%, however, over the last 30 days, the volatility rate increased by 10.94%, as shares sank -31.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.74% lower at present.
During the last 5 trading sessions, IFRX fell by -20.00%, which changed the moving average for the period of 200-days by +23.55% in comparison to the 20-day moving average, which settled at $2.2700. In addition, InflaRx N.V saw -35.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IFRX
Current profitability levels for the company are sitting at:
- -332.67 for the present operating margin
- -3.94 for the gross margin
The net margin for InflaRx N.V stands at -335.19. The total capital return value is set at -0.85. Equity return is now at value -62.38, with -54.58 for asset returns.
Based on InflaRx N.V (IFRX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -52.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1455.48.
Currently, EBITDA for the company is -44.81 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 457.98. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.31.
Conclusion
In conclusion, InflaRx N.V (IFRX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
